|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.200 GBX | +1.59% |
|
-1.54% | -54.93% |
| 29/05 | Poolbeg Pharma PLC - Shareholder/Analyst Call | |
| 27/05 | Poolbeg Pharma shares up after US FDA orphan drug designation | AN |
Projected Income Statement: Poolbeg Pharma PLC
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| EBITDA 1 | - | -4.96 | -4.66 | -5.997 | -5.4 | -5.6 |
| Change | - | - | 6.05% | -28.69% | 9.95% | -3.7% |
| EBIT 1 | - | -4.986 | -4.686 | -6.111 | -5.775 | -5.875 |
| Change | - | - | 6.02% | -30.41% | 5.5% | -1.73% |
| Interest Paid | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.777 | -4.505 | -5.944 | -5.94 | -5.75 |
| Change | - | - | 5.69% | -31.94% | 0.07% | 3.2% |
| Net income 1 | -2.336 | -4.686 | -3.931 | -5.79 | -5.94 | -5.75 |
| Change | - | -100.6% | 16.11% | -47.29% | -2.59% | 3.2% |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | 20/05/25 | - | - |
1GBP in Million
Estimates
Forecast Balance Sheet: Poolbeg Pharma PLC
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | -16.2 | -12.2 | -7.82 | -7.17 | -1.93 |
| Change | - | - | 24.69% | 35.9% | 8.36% | 73.08% |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | 20/05/25 | - | - |
1GBP in Million
Estimates
Cash Flow Forecast: Poolbeg Pharma PLC
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| CAPEX 1 | 0.597 | 0.175 | 0.129 | 0.1 | 0.1 |
| Change | - | -70.69% | -26.29% | -22.48% | 0% |
| Free Cash Flow (FCF) 1 | -4.965 | -4.556 | -4.775 | -5.1 | -5.4 |
| Change | - | 8.24% | -4.81% | -6.81% | -5.88% |
| Announcement Date | 30/03/23 | 30/04/24 | 20/05/25 | - | - |
1GBP in Million
Estimates
Forecast Financial Ratios: Poolbeg Pharma PLC
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
Profitability | ||||||
| EBITDA Margin (%) | - | - | - | - | - | - |
| EBIT Margin (%) | - | - | - | - | - | - |
| EBT Margin (%) | - | - | - | - | - | - |
| Net margin (%) | - | - | - | - | - | - |
| FCF margin (%) | - | - | - | - | - | - |
| FCF / Net Income (%) | - | 105.95% | 115.9% | 82.47% | 85.86% | 93.91% |
Profitability | ||||||
| ROA | - | - | - | - | - | - |
| ROE | - | -22.91% | -24% | -48.83% | -62.4% | -189.9% |
Financial Health | ||||||
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Debt / Free cash flow | - | - | - | - | - | - |
Capital Intensity | ||||||
| CAPEX / Current Assets (%) | - | - | - | - | - | - |
| CAPEX / EBITDA (%) | - | -12.04% | -3.76% | -2.15% | -1.85% | -1.79% |
| CAPEX / FCF (%) | - | -12.02% | -3.84% | -2.7% | -1.96% | -1.85% |
Items per share | ||||||
| Cash flow per share 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - |
| Change | - | - | - | - | - | - |
| Book Value Per Share 1 | - | 0.0366 | 0.03 | 0.0186 | 0.012 | 0.004 |
| Change | - | - | -18.03% | -38.17% | -35.31% | -66.67% |
| EPS 1 | -0.0074 | -0.0094 | -0.0079 | -0.0116 | -0.0099 | -0.0083 |
| Change | - | -27.03% | 15.96% | -46.84% | 14.66% | 16.16% |
| Nbr of stocks (in thousands) | 5,00,000 | 5,00,000 | 5,00,000 | 5,00,000 | 6,97,200 | 6,97,200 |
| Announcement Date | 02/03/22 | 30/03/23 | 30/04/24 | 20/05/25 | - | - |
1GBP
Estimates
| 2025 * | 2026 * | |
|---|---|---|
| P/E ratio | -3.23x | -3.86x |
| PBR | 2.67x | 8x |
| EV / Sales | - | - |
| Yield | - | - |
More valuation ratios
* Estimated data
EPS & Dividend
Year-on-year evolution of the PER
Annual profits - Rate of surprise
- Stock Market
- Equities
- POLB Stock
- Financials Poolbeg Pharma PLC
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition